Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. In 2018, the company's largest selling product lines were Neulasta, an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

KLOTHO Therapeutics (KTI) is a biotechnology company developing patent-pending Klotho proteins with great potential to redefine society’s experience with aging. Klotho, a naturally occurring human protein discovered in 1997, promises to delay major diseases of aging – kidney failure, Alzheimer’s, osteoporosis, cancer, hypertension and diabetes, according to published studies. For example, National Institutes of Health report Klotho-deficient animals live 25% shorter and look older while animals overexpressing Klotho live 20-30% longer. The company’s first focus is on kidney failure, one of the major causes of death in the U.S. that affects up to 30 million people per year, 600,000 of whom are currently on dialysis. There is no successful long-term therapy today. KTI has filed patents on modified Klotho proteins covering its expansive potential indications.

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

Celgene Corporation is an American biotechnology company that discovers, develops and commercializes medicines for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. The company's major product is Revlimid (lenalidomide), in combination with dexamethasone for the treatment of multiple myeloma patients. Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia, due to Low- or Intermediate-1-risk Myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Revlimid is sold through proprietary risk-management distribution programs, to ensure safe and appropriate use of these pharmaceuticals. Vidaza is approved for the treatment of patients with MDS.

Iperboreal Pharma Srl engages in medical research and development activities of life-saving medicines and hospital products for the treatment of critical illnesses and diseases. Its other study areas of interest include treatment and interventions for chronic terminal renal failure and peritoneal dialysis. The company was founded in 2003 and is headquartered in Pescara, Italy.

NGM Biopharmaceuticals is a privately-held drug discovery company committed to identifying transformational medicines that dramatically improve human health. Based on emerging human clinical and genetic observations, the company has devised several innovative experimental approaches to discover new therapies for the treatment of metabolic and cardiovascular diseases. The company's current focus is on the gastrointestinal endocrine system, with an aim to identify novel factors implicated in the pathogenesis of type 2 diabetes and the apparent resolution of this grievous disease in patients who have undergone gastric bypass surgery.

Established in 1945, Amorepacific is Korea’s No.1 beauty company and a blue-chip corporation. Amorepacific owns nearly 30 well-known brands and has been developing rapidly worldwide. Amorepacific pays great attention to product research and development through research centers located in Korea, France, Japan and Shanghai, to develop premium and high quality skincare and cosmetics products. The Group chose Hong Kong as a strategic bridgehead for the expansion of its presence across the Greater China region and the rest of the world. Two flagship brands - LANEIGE and Sulwhasoo, were introduced in Hong Kong in 2002 and 2004 respectively. The eponymous luxury brand – AMOREPACIFIC, was introduced in Hong Kong in 2014. In 2015, ETUDE HOUSE, a playful cosmetics brand, made its debut in the territory. In 2018, the Company set foot in the personal care product market, introducing the Group’s legendary hair care brand ‘Ryo’ into Hong Kong.

Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.

Cal-X Stars Business Accelerator is a business accelerator focused on cardiovascular life science and social good impact innovations. It is an innovation factory creating and nurturing breakthrough totally original disruptive technologies that address multi-billion unmet markets. Cal-X specializes in two clear sectors - cardiovascular and social good impact.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Apceth GmbH & Co. KG develops cell therapy products. It focuses on the isolation and use of adult stem cells from donors and patients for a therapy optimization in the field of therapeutic and regenerative cell therapy. The firm offers research and non clinical development services, pharmaceutical technical equipment and technology, and hold interest in translational science. The company was founded by Ralf Huss in November 2007 and is headquartered in Munich, Germany.

BioViva USA, Inc. is a company headquartered in Bainbridge Island, WA, that provides biotechnology research services. Elizabeth Parrish is the current CEO of the firm.\nThe company says this about itself: BioViva Science was founded in 2015 to tackle age-related diseases with cutting-edge gene therapies. The company has since expanded into bioinformatics and direct-to-consumer tests. BioViva and its CEO, Elizabeth Parrish, have been featured by the BBC, The London Times, Forbes, National Geographic, and The Guardian. Liz Parrish, CEO of BioViva, is a humanitarian, entrepreneur, author, innovator, and a leading voice for genetic cures. As a strong proponent of progress and education for the advancement of gene therapy, she serves as a motivational speaker to the public at large for the life sciences.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Leto Laboratories is a research team that is specialized in platform building for protein re-engineering. The company aims to fill the gaps in the treatment of cancer and rare diseases to benefit patients. Leto Labs has a diversified research team that specializes in platform development for novel protein re-engineering.

UAB Research Foundation (doing business as UABRF), a subsidiary of The University of Alabama System, is a company headquartered in Birmingham, AL. The firm engages in identify, assess, and market commercially viable technology developed at The University of Alabama at Birmingham.

Guangzhou Hongchang Biotechnology Co., Ltd., established on 2011-09-06, Business scope includes biotechnology development services;Medical Research and Experimental Development;Operation of non-licensed medical devices;Stem Cell Technology Research,to develop;Engineering and Technology Research and Experimental Development;Engineering and Technology Basic Science Research Services;Biotechnology Extension Services;Health Sciences Program Research Transfer;Technology Promotion of Research Results of Health Science Projects;Life Engineering Project Development;Medical technology promotion service;Optical Instrument Manufacturing;Sales of Biological Products(Does not include licensed operations);Research and development of biological products(Does not include licensed operations);Technology project agency service;trade agent;Licensed medical device business;